Trial Profile
A Phase I/II Study in Combination of Resminostat and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Previously Untreated With Systemic Chemotherapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Sep 2018
Price :
$35
*
At a glance
- Drugs Resminostat (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Yakult Honsha
- 10 Sep 2018 Primary endpoint (Phase 2 : Time To Progression (TTP)) has not been met, according to results published in the Investigational New Drugs.
- 10 Sep 2018 Results published in the Investigational New Drugs
- 11 Jan 2018 Status changed from active, no longer recruiting to completed.